IMR Press / RCM / Volume 24 / Issue 4 / DOI: 10.31083/j.rcm2404095
Open Access Review
Cardiovascular Effects of Excess Growth Hormone: How Real is the Threat?
Show Less
1 Department of Medicine, Lincoln Medical and Mental Health Center, Bronx, NY 10451, USA
2 Ateneo de Manila School of Medicine and Public Health, 1604 Pasig City, Philippines
3 Department of Medicine, Southern Philippines Medical Center, 8000 Davao City, Philippines
4 St. Luke’s Medical Center College of Medicine - William H. Quasha Memorial, 1102 Manila, Philippines
5 Cebu Institute of Medicine, 6000 Cebu City, Philippines
6 Section of Vascular Cell Biology, Joslin Diabetes Center and Harvard Medical School, Boston, MA 02215, USA
7 Section of Cardiology, Thomas Jefferson University, Philadelphia, PA 19107, USA
8 Section of Nephrology, University of Illinois at Chicago College of Medicine/Advocate Christ Medical Center, Oak Lawn, IL 60612, USA
9 University of Arizona, Phoenix, AZ 85004, USA
10 Truth for Health Foundation, Tucson, AZ 85728, USA
*Correspondence: frederick.berro.rivera@gmail.com (Frederick Berro Rivera)
Rev. Cardiovasc. Med. 2023, 24(4), 95; https://doi.org/10.31083/j.rcm2404095
Submitted: 29 October 2022 | Revised: 16 January 2023 | Accepted: 31 January 2023 | Published: 23 March 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Patients with acromegaly carry a high risk of developing cardiovascular diseases (CVD). In fact, CVD is the leading cause of mortality among this group of patients. The most frequent cardiovascular complications are heart failure (HF), valvular disease, hypertension, arrhythmias, and coronary artery disease (CAD). The pathophysiology centers on the family of growth hormone (GH). These hormones are involved in normal cardiac development and function; however, excess of insulin-like growth factor-1 (IGF-1), the principally active hormone, can also cause negative effects on the cardiovascular system. HF in acromegaly usually presents with biventricular enlargement and diastolic dysfunction and is strongly associated with the duration of GH excess rather than the degree of hormone elevation. There is a high prevalence of valvular disease affecting aortic and mitral valves among patients with longer disease duration. The development of hypertension in acromegaly may be attributed to the effects of chronic GH/IGF-1 excess on different organ systems, which act via several mechanisms. The aspect of arrhythmia and CAD complicating acromegaly are currently not fully understood.

Keywords
growth hormone
insulin-like growth factor-1
cardiovascular diseases
acromegaly
Figures
Fig. 1.
Share
Back to top